The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Mitigating CRS following glofitamab treatment in R/R DLBCL
Joshua Brody, MD, The Tisch Cancer Institute Mount Sinai, New York, NY, provides insights into the management of cytokine release syndrome (CRS) following glofitamab treatment in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Data from a Phase I/II study (NCT03075696) reveals that CRS can be mitigated by administering glofitamab in a step-up dosing regimen, or with prophylactic steroids, with dexamethasone being more effective than prednisone. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
Consultancy: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
